SG11201810268YA - Combination therapy with notch and pd-1 or pd-l1 inhibitors - Google Patents

Combination therapy with notch and pd-1 or pd-l1 inhibitors

Info

Publication number
SG11201810268YA
SG11201810268YA SG11201810268YA SG11201810268YA SG11201810268YA SG 11201810268Y A SG11201810268Y A SG 11201810268YA SG 11201810268Y A SG11201810268Y A SG 11201810268YA SG 11201810268Y A SG11201810268Y A SG 11201810268YA SG 11201810268Y A SG11201810268Y A SG 11201810268YA
Authority
SG
Singapore
Prior art keywords
cancer
international
indiana
indianapolis
eli lilly
Prior art date
Application number
SG11201810268YA
Inventor
Mark Harrath Bender
Hong Gao
Bharvin Kumar Patel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11201810268YA publication Critical patent/SG11201810268YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/200969 Al 23 November 2017 (23.11.2017) WIPO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 39/395 (2006.01) A61K 31/542 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61K 45/06 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: Declarations under Rule 4.17: PCT/US2017/032790 — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) (22) International Filing Date: — as to the applicant's entitlement to claim the priority of the 16 May 2017 (16.05.2017) earlier application (Rule 4.17(iii)) (25) Filing Language: English Published: — (26) Publication Language: English with international search report (Art. 2 I (3)) (30) Priority Data: 62/339,363 20 May 2016 (20.05.2016) US (71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). (72) Inventors: BENDER, Mark Harrath; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). GAO, Hong; c/o Eli Lilly and Compa- ny, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). PATEL, Bharvin Kumar; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). (74) Agent: DEMETER, John C. et al.; Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). Designated States indicated, (81) (unless otherwise for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States indicated, (84) (unless otherwise for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, ZM, ZW), Eurasian AZ, BY, KG, KZ, RU, TJ, UG, (AM, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, ,_ 1 (54) Title: COMBINATION THERAPY WITH NOTCH AND PD-1 OR PD-L1 INHIBITORS (57) : The present invention provides medicaments for use in treating and methods of treating T- cell acute lymphoblas- S tic leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous cN leukemia, erythroleukemia, triple negative breast cancer, breast cancer, ovarian cancer, melanoma, Sung cancer, non small-cell lung © cancer, pancreatic cancer, glioblastoma, colorectal cancer, head and neck cancer, cervical cancer, prostate cancer, liver cancer, oral 0 squamous cell carcinoma, skin cancer, medul!ob!astoma, hepatocellular carcinoma, intrahepatic and extrahepatic cholangiocarcino- ei --.... ma, desmoid tumor, soft tissue sarcoma, or adenoid cystic carcinoma in a patient comprising combination therapy with 4,4,4-tri- Ir - fluoro-N-K1S)-2—[[(7S)-5-(2-hydroxyemy1)-6-oxo-7H-pyrido [23-d] [3]benzazepin-7-yl]amino]-1-methyl-2-oxo- ethyljbutanamide, or 1-1 O a pharmaceutically acceptable salt or hydrate thereof, and a PD-1 or a PD-L1 inhibitor selected from pembrolizumab, nivolumab, ate- el zolizumab, durvalumab, and avelumab. C
SG11201810268YA 2016-05-20 2017-05-16 Combination therapy with notch and pd-1 or pd-l1 inhibitors SG11201810268YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662339363P 2016-05-20 2016-05-20
PCT/US2017/032790 WO2017200969A1 (en) 2016-05-20 2017-05-16 Combination therapy with notch and pd-1 or pd-l1 inhibitors

Publications (1)

Publication Number Publication Date
SG11201810268YA true SG11201810268YA (en) 2018-12-28

Family

ID=58772978

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810268YA SG11201810268YA (en) 2016-05-20 2017-05-16 Combination therapy with notch and pd-1 or pd-l1 inhibitors

Country Status (14)

Country Link
US (2) US10688104B2 (en)
EP (1) EP3458091B1 (en)
JP (1) JP7194022B2 (en)
KR (1) KR102463617B1 (en)
CN (2) CN115845070A (en)
AU (1) AU2017268187A1 (en)
BR (1) BR112018073673A2 (en)
CA (1) CA3025024A1 (en)
ES (1) ES2904880T3 (en)
IL (1) IL263110B (en)
MA (1) MA45025A (en)
MX (1) MX2018013941A (en)
SG (1) SG11201810268YA (en)
WO (1) WO2017200969A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI609687B (en) 2015-04-14 2018-01-01 美國禮來大藥廠 Targeted treatment of leiomyosarcoma
KR20180040138A (en) 2015-07-13 2018-04-19 싸이톰스 테라퓨틱스, 인크. Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of using them
CN109310684B (en) 2016-04-12 2021-11-19 伊莱利利公司 Combination therapy of NOTCH and CDK4/6 inhibitors for the treatment of cancer
AU2017249988C1 (en) 2016-04-12 2023-02-16 Eli Lilly And Company Combination therapy with notch and PI3K/mTOR inhibitors for use in treating cancer
IL263110B (en) 2016-05-20 2022-07-01 Lilly Co Eli Combination therapy with notch and pd-1 or pd-l1 inhibitors
WO2018071307A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
EP3582782B1 (en) 2017-02-17 2023-06-07 Fred Hutchinson Cancer Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
WO2019122998A1 (en) * 2017-12-18 2019-06-27 Debiopharm International Sa Combination of an agonist anti-pd-1 antibody with a gnrh agonist or antagonist to treat cancer
BR112023020922A2 (en) * 2021-04-28 2023-12-12 Obi Pharma Inc PHARMACEUTICAL COMPOSITION, USE OF THE PHARMACEUTICAL COMPOSITION, METHOD FOR TREATING CANCER IN A PATIENT IN NEED OF THE SAME, AND METHOD FOR INHIBITING THE GROWTH OF CANCER CELLS

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129820A0 (en) 1996-12-23 2000-02-29 Elan Pharm Inc Cycloalkyl lactam lactone and related compounds as beta-amyloid peptide release inhibitors
CA2343963A1 (en) 1998-10-02 2000-04-13 The Government Of The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, The National Institutes Of Health Apotosis inducing agents and methods
ES2367430T3 (en) 2002-12-23 2011-11-03 Wyeth Llc ANTIBODIES AGAINST PD-1 AND ITS USES.
GB0303663D0 (en) * 2003-02-18 2003-03-19 Lorantis Ltd Assays and medical treatments
ES2427646T5 (en) 2005-05-09 2017-08-22 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies against programmed death 1 (PD1) and methods for the treatment of cancer through the use of anti-PD-1 antibodies alone or in combination with other immunotherapeutic agents
MX2007015942A (en) 2005-07-01 2008-03-07 Medarex Inc Human monoclonal antibodies to programmed death ligand 1 (pd-l1).
EP1907432B1 (en) 2005-07-05 2011-12-07 FUJIFILM Corporation Copolymer and polymerizable composition
DE102006002966A1 (en) * 2006-01-21 2007-07-26 Schaeffler Kg Running disk with integrated rolling element raceway
US8633179B2 (en) 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
EP2954900A1 (en) 2007-03-28 2015-12-16 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
RS53072B (en) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
MX2010001754A (en) 2007-08-14 2010-05-14 Lilly Co Eli Azepine derivatives as gamma-secretase inhibitors.
MA33076B1 (en) 2008-01-11 2012-03-01 Hoffmann La Roche USE OF A GAMMA SECRETASE INHIBITOR FOR THE TREATMENT OF CANCER
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
HUE034832T2 (en) 2008-12-09 2021-12-28 Hoffmann La Roche Anti-pd-l1 antibodies and their use to enhance t-cell function
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
US8741295B2 (en) 2009-02-09 2014-06-03 Universite De La Mediterranee PD-1 antibodies and PD-L1 antibodies and uses thereof
EP2470054B1 (en) 2009-08-26 2013-12-04 FrXsh AG Device and method for mixing material to be mixed
US8637493B2 (en) 2009-11-12 2014-01-28 University Of Massachusetts Methods for treating glioblastoma
ES2646863T3 (en) 2009-11-24 2017-12-18 Medimmune Limited B7-H1 specific binding agents
CN102085372A (en) 2009-12-04 2011-06-08 中国医学科学院基础医学研究所 Application of Notch pathway inhibitor in treatment of tumors caused by activation of mTOR
US9163087B2 (en) * 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
JO3003B1 (en) 2011-01-14 2016-09-05 Lilly Co Eli Imidazo [4,5-c] quinolin-2-one compound and its use as pi3 kinase i mtor dual inhibitor
AR087107A1 (en) * 2011-07-27 2014-02-12 Lilly Co Eli INHIBITOR COMPOUND OF THE SIGNALING OF THE NOTCH TRAJECTORY
CN103842030B (en) * 2011-08-01 2018-07-31 霍夫曼-拉罗奇有限公司 Use the method for PD-1 axis binding antagonists and mek inhibitor treating cancer
JP6138813B2 (en) 2011-11-28 2017-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Anti-PD-L1 antibody and use thereof
EP3003316B1 (en) * 2013-05-31 2020-07-22 Merck Sharp & Dohme Corp. Combination therapies for cancer
US9698876B2 (en) 2013-07-23 2017-07-04 Telefonaktiebolaget Lm Ericsson (Publ) Transmission mode allocation in LTE networks
AU2014309199B2 (en) * 2013-08-20 2018-04-19 Merck Sharp & Dohme Llc Treating cancer with a combination of a PD-1 antagonist and dinaciclib
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
WO2015117164A1 (en) * 2014-02-03 2015-08-06 Memorial Sloan-Kettering Cancer Center Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
CN106488775A (en) 2014-07-11 2017-03-08 基因泰克公司 NOTCH approach suppresses
RU2751660C2 (en) 2014-07-21 2021-07-15 Новартис Аг Treatment of malignant neoplasm using humanized chimeric antigen receptor against bcma
US9465158B2 (en) * 2014-09-04 2016-10-11 National Taiwan Normal University Light-guide coupler for modulating angular and spatial distributions of light source
CN107206071A (en) * 2014-09-13 2017-09-26 诺华股份有限公司 The conjoint therapy of ALK inhibitor
US10828352B2 (en) * 2014-10-27 2020-11-10 Fred Hutchinson Cancer Research Center Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy
AU2015338974B2 (en) * 2014-10-31 2021-08-26 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
SG11201704548PA (en) 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
EP3280795B1 (en) 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
TWI609687B (en) 2015-04-14 2018-01-01 美國禮來大藥廠 Targeted treatment of leiomyosarcoma
SG10201913841SA (en) 2015-07-24 2020-03-30 Oncotracker Inc Gamma secretase modulators for the treatment of immune system dysfunction
CN109310684B (en) 2016-04-12 2021-11-19 伊莱利利公司 Combination therapy of NOTCH and CDK4/6 inhibitors for the treatment of cancer
AU2017249988C1 (en) 2016-04-12 2023-02-16 Eli Lilly And Company Combination therapy with notch and PI3K/mTOR inhibitors for use in treating cancer
IL263110B (en) 2016-05-20 2022-07-01 Lilly Co Eli Combination therapy with notch and pd-1 or pd-l1 inhibitors
EP3506905B1 (en) 2016-08-31 2024-03-20 Eli Lilly and Company Dosage regimen for the treatment of solid tumors
WO2018071307A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
AU2018359907A1 (en) 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor

Also Published As

Publication number Publication date
EP3458091A1 (en) 2019-03-27
JP2019516733A (en) 2019-06-20
IL263110A (en) 2018-12-31
CN109475629A (en) 2019-03-15
US11826317B2 (en) 2023-11-28
KR102463617B1 (en) 2022-11-03
MX2018013941A (en) 2019-03-21
US20190192531A1 (en) 2019-06-27
CA3025024A1 (en) 2017-11-23
KR20190008913A (en) 2019-01-25
JP7194022B2 (en) 2022-12-21
CN115845070A (en) 2023-03-28
EP3458091B1 (en) 2021-11-17
WO2017200969A1 (en) 2017-11-23
MA45025A (en) 2019-03-27
BR112018073673A2 (en) 2019-02-26
AU2017268187A1 (en) 2018-11-29
ES2904880T3 (en) 2022-04-06
IL263110B (en) 2022-07-01
US20220008432A1 (en) 2022-01-13
US10688104B2 (en) 2020-06-23

Similar Documents

Publication Publication Date Title
SG11201810268YA (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201804647TA (en) Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201811225RA (en) Ar+ breast cancer treatment methods
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201807965YA (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201811559WA (en) Cancer treatment combinations
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201809162XA (en) 6-aminopyridin-3-yl thiazoles as modulators of ror?t
SG11201810940XA (en) Methods of treating pancreatic cancer